# Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11

> **NCT06440187** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 38 (actual)

## Conditions studied

- Recurrent or Metastatic Nasopharyngeal Carcinom

## Interventions

- **DRUG:** Gemcitabine+ nivolumab

## Key facts

- **NCT ID:** NCT06440187
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-08
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06440187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06440187, "Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06440187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*